What's in Ahmed AbdelMoneim Hassan Ali's pipeline?

Ahmed AbdelMoneim Hassan Ali has 1 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Ahmed AbdelMoneim Hassan Ali's portfolio?

Top competitors by shared drug class: Bayer, Chang Gung Memorial Hospital, Charles University, Czech Republic, Daiichi Sankyo Co., Ltd., Florida Orthopaedic Institute.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/ahmed-abdelmoneim-hassan-ali.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Ahmed AbdelMoneim Hassan Ali — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ahmed AbdelMoneim Hassan Ali pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Rivaroxaban 10 Milligrams	Rivaroxaban 10 Milligrams	phase 3	Direct Factor Xa inhibitor	Factor Xa	Cardiovascular

Therapeutic area mix

Cardiovascular · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Bayer · 1 shared drug class
Chang Gung Memorial Hospital · 1 shared drug class
Charles University, Czech Republic · 1 shared drug class
Daiichi Sankyo Co., Ltd. · 1 shared drug class
Florida Orthopaedic Institute · 1 shared drug class
McMaster University · 1 shared drug class
Rennes University Hospital · 1 shared drug class
Swiss Paraplegic Research, Nottwil · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Ahmed AbdelMoneim Hassan Ali:

Cite this brief

Drug Landscape (2026). Ahmed AbdelMoneim Hassan Ali — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ahmed-abdelmoneim-hassan-ali. Accessed 2026-05-17.